Robin Chusid, 55, fought cancer for about a year. She seemed to have won, and danced at her son's wedding one week after her last chemotherapy treatment in October.

But Chusid said she's always afraid. Ovarian cancer recurs in 70 percent of women in remission, according to data from the nonprofit Ovarian Cancer Research Fund Alliance. The odds, she said, seem stacked against her.

Now the wife of Coral Springs litigator Mitchel Chusid is gearing for another fight, this time with Blue Cross and Blue Shield of Florida Inc. for denying coverage of a $15,600-per-month drug. Her husband's 40-page class action lawsuit filed June 13 in Broward Circuit Court includes medical records and asks the court for two things: a finding that the insurance company violated Florida's Deceptive and Unfair Trade Practices Act and a declaration forcing Blue Cross to cover a drug called Zejula, which the Food and Drug Administration approved in March to treat relapsed ovarian cancer patients and those in remission.